Table 5.
Evidence of genes containing sentinel variants for roles in hypertension.
| Gene | Evidence of role in hypertension |
|---|---|
| COL6A1 | Encodes a collagen VI protein and provides structural support for a variety of tissues including the heart; has been shown previously, in addition to other VEGF-A pathway genes, to be associated with atrioventricular septal defect (AVSD) in patients with Down syndrome [63] |
| SLC28A3 | Encodes a sodium-dependent nucleoside transporter (NT); NTs have many physiological regulatory roles including that of mediating adenosine concentration, which in turn affects vascular tone [64, 65] |
| SEL1L3 | Differentially expressed between male familial combined hyperlipidemia and coronary heart disease (FCHL-CHD) patients and non-FCHL-non-CHD controls in a microarray study [66]. Also upregulated with a >6-fold expression change in a rabbit microarray study comparing simulating conditions before and after repair of coarctation of the aorta, a condition which may evolve into chronic hypertension [67]; as the authors stated, despite the surgically induced return to normal BP, the vasculature still retains its physical defects, and this gene may thus play a role in the continued residual effects. |
| YOD1 | A deubiquitinase, targeted by miR-21 in the distal small pulmonary arteries of mice with pulmonary arterial hypertension exposed to hypoxic conditions, as well as in human pulmonary artery smooth muscle cells with transfected miR-21 [68]. |
| CCDC13 | Encodes a centriolar satellite protein involved in primary ciliogenesis [44]; this supports a potential role in hypertension present in individuals with autosomal dominant polycystic kidney disease, in which impaired primary cilia affects vascular tone [70, 71] |
| QSOX1 | Recent experiments support cardiovascular function for QSOX1, encoding a sulfhydryl oxidase enzyme; one such function includes its induction of vascular smooth muscle cell migration and proliferation in vitro [72], a potential role in atherosclerosis [73], and its feasibility as a biomarker for acute decompensated heart failure [74, 75]. |